Foresite Capital
Healthcare investment firm founded by Jim Tananbaum (GreenLight Biosciences, Theravance founder), focused on precision medicine, genomics, and transformative healthcare companies. Deep expertise across therapeutics, diagnostics, and healthcare services.
Website
https://foresitecapital.comLocation
San Francisco, USA
Founded
2011
AUM
$5B+
Investment Range
$10M - $100M
Portfolio Companies
3
Focus
biotech-focused
Fund Stages
series-a, series-b, series-c, growth
Investment Thesis
Foresite Capital invests across the healthcare spectrum with a focus on precision medicine, genomics, and data-driven healthcare companies. They take concentrated positions in companies with transformative potential, leveraging their team's deep operating experience and scientific expertise.
Team
Partners / Managing Directors (Health & Bio Focus)
- Jim Tananbaum, MD - Founder & CEO
- Dennis Ryan - Managing Director
- Michael Rome - Managing Director
- Matt Portnoy - Managing Director
Other Key Team Members
- Investment team with MD/PhD expertise
Focus Areas
- Precision Medicine
- Genomics
- Therapeutics
- Diagnostics
- Healthcare Technology
- Life Science Tools
- Data-Driven Healthcare
Notable Exits
- Guardant Health - IPO (2018, NASDAQ: GH) - liquid biopsy leader
- Grail - Acquired (2021, by Illumina for $8B)
- Adaptive Biotechnologies - IPO (2019, NASDAQ: ADPT)
- 10x Genomics - IPO (2019, NASDAQ: TXG)
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| 10x Genomics | Pleasanton, California, USA | 2012 | genomics-sequencingbiotech+1 |
| Twist Bioscience | South San Francisco, California, USA | 2013 | genomics-sequencingbiotech+3 |
| Eikon Therapeutics | Hayward, California, USA | 2019 | drug-discoveryai-drug-discovery+3 |